Clinical Trial Update: Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

View source ↗

Summary

A recruiting clinical trial evaluating treatment effectiveness in axial spondyloarthritis and psoriatic arthritis patients starting one of five therapies: bimek…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Psoriatic Arthritis

Drugs mentioned

• Bimekizumab (bimekizumab)
• Guselkumab (guselkumab)
• Risankizumab (risankizumab)
• TNF inhibitor (tumor necrosis factor inhibitor)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: Adelphi Real World | Conditions: Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA) | Status: RECRUITING